Preclinical Safety Evaluation of AAV2-sFLT01— A Gene Therapy for Age-related Macular Degeneration
Open Access
- 1 February 2011
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 19 (2), 326-334
- https://doi.org/10.1038/mt.2010.258
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillarisProceedings of the National Academy of Sciences of the United States of America, 2009
- HumanRPE65Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 YearHuman Gene Therapy, 2009
- Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and PhotoreceptorsPLOS ONE, 2008
- Treatment of Leber Congenital Amaurosis Due toRPE65Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I TrialHuman Gene Therapy, 2008
- Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vesselsJournal of Cellular Physiology, 2008
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisThe New England Journal of Medicine, 2008
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisThe New England Journal of Medicine, 2008
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- Long-term Evaluation of AAV-Mediated sFlt-1 Gene Therapy for Ocular Neovascularization in Mice and MonkeysMolecular Therapy, 2005